These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 8753810

  • 1. A RING finger motif regulates transforming activity of the rfp/ret fusion gene.
    Hasegawa N, Iwashita T, Asai N, Murakami H, Iwata Y, Isomura T, Goto H, Hayakawa T, Takahashi M.
    Biochem Biophys Res Commun; 1996 Aug 14; 225(2):627-31. PubMed ID: 8753810
    [Abstract] [Full Text] [Related]

  • 2. Mouse ret finger protein (rfp) proto-oncogene is expressed at specific stages of mouse spermatogenesis.
    Cao T, Shannon M, Handel MA, Etkin LD.
    Dev Genet; 1996 Aug 14; 19(4):309-20. PubMed ID: 9023983
    [Abstract] [Full Text] [Related]

  • 3. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA.
    Mol Cell Biol; 1996 May 14; 16(5):2151-63. PubMed ID: 8628282
    [Abstract] [Full Text] [Related]

  • 4. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M, Takeda K, Kawamoto Y, Iwashita T, Akhand AA, Senga T, Yamamoto M, Sobue G, Hamaguchi M, Takahashi M, Nakashima I.
    Cancer Res; 2002 Apr 15; 62(8):2414-22. PubMed ID: 11956105
    [Abstract] [Full Text] [Related]

  • 5. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, Gishizky ML, Pierotti MA, Borrello MG.
    Oncogene; 2001 Jun 14; 20(27):3475-85. PubMed ID: 11429694
    [Abstract] [Full Text] [Related]

  • 6. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA.
    Oncogene; 1998 Sep 03; 17(9):1079-87. PubMed ID: 9764818
    [Abstract] [Full Text] [Related]

  • 7. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M.
    Oncogene; 1996 Feb 01; 12(3):481-7. PubMed ID: 8637703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M.
    Hum Mol Genet; 1999 Oct 15; 8(11):1989-99. PubMed ID: 10484767
    [Abstract] [Full Text] [Related]

  • 15. Ret-mediated mitogenesis requires Src kinase activity.
    Melillo RM, Barone MV, Lupoli G, Cirafici AM, Carlomagno F, Visconti R, Matoskova B, Di Fiore PP, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 1999 Mar 01; 59(5):1120-6. PubMed ID: 10070972
    [Abstract] [Full Text] [Related]

  • 16. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M.
    Endocrinology; 1998 Aug 01; 139(8):3613-9. PubMed ID: 9681515
    [Abstract] [Full Text] [Related]

  • 17. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I.
    Mol Cell Biol; 2001 Jul 01; 21(13):4177-87. PubMed ID: 11390647
    [Abstract] [Full Text] [Related]

  • 18. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
    Kato M, Iwashita T, Takeda K, Akhand AA, Liu W, Yoshihara M, Asai N, Suzuki H, Takahashi M, Nakashima I.
    Mol Biol Cell; 2000 Jan 01; 11(1):93-101. PubMed ID: 10637293
    [Abstract] [Full Text] [Related]

  • 19. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, Munnich A, Lenoir G, Lyonnet S, Billaud M.
    J Clin Invest; 1998 Mar 15; 101(6):1415-23. PubMed ID: 9502784
    [Abstract] [Full Text] [Related]

  • 20. The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane.
    Monaco C, Visconti R, Barone MV, Pierantoni GM, Berlingieri MT, De Lorenzo C, Mineo A, Vecchio G, Fusco A, Santoro M.
    Oncogene; 2001 Feb 01; 20(5):599-608. PubMed ID: 11313992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.